Novel non-operative treatment and treatment strategies in pancreatic cancer

被引:6
作者
Bramhall, SR [1 ]
机构
[1] Queen Elizabeth Hosp, Dept Surg, Birmingham B15 2TH, W Midlands, England
关键词
chemotherapy; molecular biology; novel treatments; pancreatic cancer;
D O I
10.1517/13543784.9.6.1179
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Patients with advanced pancreatic cancer have traditionally been treated with palliative care only. The last decade has seen significant improvements in the surgical treatment of this disease but until the late 1990s there was no effective non-surgical treatment for these rumours. The introduction of gemcitabine has given clinicians treating patients with pancreatic cancer a new option. The published randomised data of gemcitabine in patients with pancreatic cancer has shown both a small survival advantage and significant improvements in quality of life indicators in these patients. These data have stimulated a resurgence of interest in pancreatic tumours and several studies have been or are currently investigating novel treatments or treatment, strategies. The explosion in the molecular knowledge of cancer has led to the development of several 'molecular designer drugs' that have been tested in pancreatic cancer. The furthest advanced of these is a matrix metalloproteinase (MMP) inhibitor called marimastat. The first randomised data using this new class of agents is increasing and suggests that marimastat may have a role in the future treatment of patients with pancreatic cancer. Other agents such as gastrimmune, are about to enter Phase III studies and several other molecular treatment strategies are progressing from the in vitro stage towards the clinical arena. Each of these treatments and treatment regimens are discussed along with their current progress.
引用
收藏
页码:1179 / 1195
页数:17
相关论文
共 165 条
[1]   TUMOR-CELL INVASION INHIBITED BY TIMP-2 [J].
ALBINI, A ;
MELCHIORI, A ;
SANTI, L ;
LIOTTA, LA ;
BROWN, PD ;
STETLERSTEVENSON, WG .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (11) :775-779
[2]   INHIBITION OF COLLAGENOLYTIC ACTIVITY AND METASTASIS OF TUMOR-CELLS BY A RECOMBINANT HUMAN TISSUE INHIBITOR OF METALLOPROTEINASES [J].
ALVAREZ, OA ;
CARMICHAEL, DF ;
DECLERCK, YA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (07) :589-595
[3]   Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene [J].
Aoki, K ;
Yoshida, T ;
Matsumoto, N ;
Ide, H ;
Hosokawa, K ;
Sugimura, T ;
Terada, M .
HUMAN GENE THERAPY, 1997, 8 (09) :1105-1113
[4]   CHEMOTHERAPY FOR PANCREATIC-CANCER [J].
ARBUCK, SG .
BAILLIERES CLINICAL GASTROENTEROLOGY, 1990, 4 (04) :953-968
[5]   ACTIVATION BY THYMIDINE KINASE AND POTENT ANTIHERPETIC ACTIVITY OF 2'-NOR-2'-DEOXYGUANOSINE (2'NDG) [J].
ASHTON, WT ;
KARKAS, JD ;
FIELD, AK ;
TOLMAN, RL .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1982, 108 (04) :1716-1721
[6]  
AUSTIN EA, 1993, MOL PHARMACOL, V43, P380
[7]   ADJUVANT COMBINATION CHEMOTHERAPY (AMF) FOLLOWING RADICAL RESECTION OF CARCINOMA OF THE PANCREAS AND PAPILLA OF VATER - RESULTS OF A CONTROLLED, PROSPECTIVE, RANDOMIZED MULTICENTER STUDY [J].
BAKKEVOLD, KE ;
ARNESJO, B ;
DAHL, O ;
KAMBESTAD, B .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (05) :698-703
[8]   ABNORMALITIES OF THE P53 TUMOR SUPPRESSOR GENE IN HUMAN PANCREATIC-CANCER [J].
BARTON, CM ;
STADDON, SL ;
HUGHES, CM ;
HALL, PA ;
OSULLIVAN, C ;
KLOPPEL, G ;
THEIS, B ;
RUSSELL, RCG ;
NEOPTOLEMOS, J ;
WILLIAMSON, RCN ;
LANE, DP ;
LEMOINE, NR .
BRITISH JOURNAL OF CANCER, 1991, 64 (06) :1076-1082
[9]   RESULTS OF RESECTION FOR CANCER OF THE EXOCRINE PANCREAS - A STUDY FROM THE FRENCH-ASSOCIATION-OF-SURGERY [J].
BAUMEL, H ;
HUGUIER, M ;
MANDERSCHEID, JC ;
FABRE, JM ;
HOURY, S ;
FAGOT, H .
BRITISH JOURNAL OF SURGERY, 1994, 81 (01) :102-107
[10]   CANCER STATISTICS, 1993 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (01) :7-26